Clinical Trial Update: Feasibility Study on the Use of Redormin®500 on Day-time Cognition [Phase 4]

View source ↗

Summary

Phase 4 feasibility study investigating Redormin 500 for daytime cognition in sleep and circadian rhythm disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Circadian Rhythm Disorders
• Cognitive Dysfunction
• Sleep Disorders

Drugs mentioned

• Redormin (Redormin)

Snippet

Sponsor: Max Zeller Soehne AG | Conditions: Sleep Disorders, Circadian Rhythm, Cognitive Dysfunction | Phase 4 | Status: COMPLETED